Skip to main content
Candice D. Fike

Candice D. Fike, MD

Languages spoken: English

Academic Information

Departments Primary - Pediatrics

Divisions: Neonatology

Board Certification

  • American Board of Pediatrics (Pediatrics)
  • American Board of Pediatrics (Sub: Neonatal-Perinatal Medicine)
  • National Board of Medical Examiners

Research Interests

  • Maturational Changes in Regulation of Pulmonary Vascular Tone
  • Regulation of Lung Fluid Balance in Newborns
  • Chronic Hypoxia-Induced Pulmonary Hypertension in Newborns
  • Role of Arachidonates and Reactive Oxygen Species in Neonatal Pulmonary Hypertension
  • Client Protein Interaction and Regulation of Vascular Tone in the Neonatal Lung
  • Impaired Nitric Oxide Function and Neonatal Pulmonary Hypertension
  • NADPH Oxidases, Oxidant Stress and Neonatal Pulmonary Hypertension
  • Citrulline Homeostasis and Chronic Neonatal Pulmonary Hypertension

Dr. Fike received her medical degree from the University of Colorado Health Sciences Center in Denver, Colorado and completed her Pediatric residency at the University of Arizona Health Sciences Center in Tucson, Arizona. She then completed a Neonatology fellowship at Baylor College of Medicine in Houston, TX followed by a research fellowship at the Cardiovascular Research Institute at the University of California, San Francisco. She has been on the faculty in the Dept. of Pediatrics at Baylor College of Medicine, the University of Utah School of Medicine, the Medical College of Wisconsin, Wake Forest University Medical School, and Vanderbilt University School of Medicine. Dr. Fike’s clinical interests include improving the care of infants with chronic lung diseases and chronic forms of pulmonary hypertension. She is particularly interested in applying knowledge gained from pre-clinical development studies performed in her laboratory to improve the outcome for infants with pulmonary hypertension associated with chronic cardiopulmonary conditions. She is also interested in improving the continuity of clinical care for newborns with complex chronic conditions, including those with chronic lung and pulmonary vascular diseases.

Education History

Research Fellow Cardiovascular Research Institute, University of California, San Francisco School of Medicine
Postdoctoral Research Fellow
Postdoctoral Fellowship Baylor College of Medicine
Postdoctoral Fellow
Residency University of Arizona Health Sciences Center
Resident
Internship University of Arizona Health Sciences Center
Intern
Professional Medical University of Colorado School of Medicine
MD
Undergraduate Rice University
BA

Selected Publications

Journal Article

  1. Fike CD, Aschner JL, Avachat C, Birnbaum AK, Sherwin CMT (2023). Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia. J Perinatol, 44(2), 280-287. (Read full article)
  2. Douglass MS, Kaplowitz MR, Zhang Y, Fike CD (2023). Impact of l-citrulline on nitric oxide signaling and arginase activity in hypoxic human pulmonary artery endothelial cells. Pulm Circ, 13(2), e12221. (Read full article)
  3. Fike CD, Avachat C, Birnbaum AK, Aschner JL, Sherwin CM (2022). Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension. Paediatr Drugs, 25(1), 87-96. (Read full article)
  4. Douglass M, Dikalova A, Kaplowitz MR, Zhang Y, Cunningham G, Summar M, Fike CD (2021). Folic acid, either solely or combined with L-citrulline, improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs. Physiol Rep, 9(21), e15096. (Read full article)
  5. Douglass MS, Zhang Y, Kaplowitz MR, Fike CD (2021). L-citrulline increases arginase II protein levels and arginase activity in hypoxic piglet pulmonary artery endothelial cells. Pulm Circ, 11(2), 20458940211006289. (Read full article)
  6. McClellan EB, Wang Z, Albertine KH, Kaplowitz MR, Zhang Y, Fike CD (2020). l-Citrulline treatment alters the structure of the pulmonary circulation in hypoxic newborn pigs. Pediatr Pulmonol, 55(10), 2762-2772. (Read full article)
  7. Dikalova A, Aschner JL, Kaplowitz MR, Cunningham G, Summar M, Fike CD (2020). Combined l-citrulline and tetrahydrobiopterin therapy improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs. Am J Physiol Lung Cell Mol Physiol, 318(4), L762-L772. (Read full article)

Review

  1. Fike CD, Aschner JL (2023). Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future. [Review]. Pharmaceuticals (Basel), 16(4). (Read full article)
  2. Rashid J, Kumar SS, Job KM, Liu X, Fike CD, Sherwin CMT (2020). Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review. [Review]. Paediatr Drugs, 22(3), 279-293. (Read full article)

Patent

  1. Summar, Marshall, Barr, Frederic E., Fike, Candice D., Aschner, Judy L (2010). Therapeutic treatment for lung conditions. U.S. Patent No. 09707788.7-2107 PCT/US2009032824. Washington, D.C.:U.S. Patent and Trademark Office.